ContextVision partners with University of Waterloo in Canada and InPhase Solutions AS in Norway to advance ultrasound diagnostics for MASLD

07 Apr 2025 08:00 CEST

ContextVision, a global leader in medical imaging solutions, is strengthening
its research ecosystem by establishing key partnerships with ultrasound data
scientists and clinical experts. These collaborations will accelerate the
development of ContextVision's AI-based solutions capable of interpreting organ
-specific ultrasound imaging datasets, with a first focus on optimizing data
quality for the diagnosis of metabolic dysfunction-associated steatotic liver
disease (MASLD).

As part of this initiative, ContextVision has signed a research agreement with
the University of Waterloo's Laboratory on Innovative Technology in Medical
Ultrasound (LITMUS) in Canada. This collaboration will augment technical and
clinical expertise in ultrasound to evolve advanced liver imaging.

Additionally, the company has partnered with InPhase Solutions AS, a Norway
-based expert in ultrasound technology development and consultancy. InPhase will
provide specialized support to enhance ContextVision's internal R&D efforts,
strengthening its capabilities in quantitative imaging and AI-powered ultrasound
technologies.

These partnerships are part of ContextVision's broader strategy to engage with
global ultrasound players, securing additional expertise and analytical support,
and to drive advancements in data quality and clinical applications for
ultrasound-based solutions.

Strengthening the Ecosystem for Liver Disease Diagnostics

"This project connects all the right dots: the increasing importance of easy
-access liver disease diagnostics, a state-of-the-art ultrasonic dataset, and AI
-based analysis," said Marco M. Voormolen, CEO of InPhase Solutions AS. "We at
InPhase Solutions are most excited to be part of this initiative."

"This partnership is an excellent example of academia and industry working
together to bring potentially life-changing solutions to clinical practice,"
said Dr. Alfred Yu, principal investigator of LITMUS and a professor of
biomedical engineering in Waterloo's Faculty of Engineering. "We are looking
forward to applying our next-generation quantitative ultrasound techniques as
part of this collaboration to enhance MASLD diagnostics."


Expanding the Data Quality Initiative

ContextVision's expansion into data quality represents a strategic shift beyond
its established role in image quality. In January 2025, the company announced
its first major research partnership in this field, collaborating with the
University of Washington's School of Medicine to advance MASLD diagnostics by
developing ultrasound-based biomarkers. The new agreements with LITMUS and
InPhase Solutions build upon this foundation, further solidifying
ContextVision's commitment to improving ultrasound-based disease quantification.

"Building a strong research ecosystem is key to advancing the next generation of
ultrasound diagnostics," said Gerald Pötzsch, CEO of ContextVision. "By bringing
together top-tier academic expertise and industry-leading technological
capabilities, we are creating the foundation for breakthrough innovations in
liver disease quantification. These partnerships mark the beginning of a growing
network that will expand further in the near future."

With MASLD affecting an estimated 25% of the global population and rising[1],
there is a growing demand for accessible, non-invasive diagnostic solutions.
ContextVision's work in data quality and quantitative imaging aims to bridge
this gap, leveraging AI-driven analysis to enhance diagnostic precision and
improve patient outcomes.

For more information, please contact:
Gerald Pötzsch
Chief Executive Officer, ContextVision
gerald.potzsch@contextvision.com

About ContextVision
ContextVision is a software company specialized in image analysis and artificial
intelligence. As the global market leader within image enhancement, we are a
trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment
around the world. Our expertise is to develop powerful software products, based
on proprietary technology and artificial intelligence for image-based
applications. Our cutting-edge technology helps clinicians accurately interpret
medical images, a crucial foundation for better diagnosis and treatment. The
company, established in 1983, is based in Sweden with local representation in
the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock
Exchange under the ticker CONTX.

[1] https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/hcc
-metabolic-dysfunction-associated-steatotic

More information:
Access the news on Oslo Bors NewsWeb site